Basilea Pharmaceutica Ag Stock Probability of Future Pink Sheet Price Finishing Over 52.44
| BPMUF Stock | USD 52.83 0.00 0.00% |
Basilea |
Basilea Pharmaceutica Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Basilea Pharmaceutica for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Basilea Pharmaceutica can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the revenue of 148.12 M. Net Loss for the year was (6.83 M) with profit before overhead, payroll, taxes, and interest of 30.89 M. | |
| Basilea Pharmaceutica AG has accumulated about 140.74 M in cash with (32.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.89. |
Basilea Pharmaceutica Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Basilea Pink Sheet often depends not only on the future outlook of the current and potential Basilea Pharmaceutica's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Basilea Pharmaceutica's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 11.8 M | |
| Short Long Term Debt | 123.5 M |
Basilea Pharmaceutica Technical Analysis
Basilea Pharmaceutica's future price can be derived by breaking down and analyzing its technical indicators over time. Basilea Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Basilea Pharmaceutica AG. In general, you should focus on analyzing Basilea Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Basilea Pharmaceutica Predictive Forecast Models
Basilea Pharmaceutica's time-series forecasting models is one of many Basilea Pharmaceutica's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Basilea Pharmaceutica's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Basilea Pharmaceutica
Checking the ongoing alerts about Basilea Pharmaceutica for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Basilea Pharmaceutica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| The company reported the revenue of 148.12 M. Net Loss for the year was (6.83 M) with profit before overhead, payroll, taxes, and interest of 30.89 M. | |
| Basilea Pharmaceutica AG has accumulated about 140.74 M in cash with (32.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.89. |
Other Information on Investing in Basilea Pink Sheet
Basilea Pharmaceutica financial ratios help investors to determine whether Basilea Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Basilea with respect to the benefits of owning Basilea Pharmaceutica security.